Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals Holdings, Inc. will partake in the 2024 RBC Capital Markets Global Healthcare Conference. Yuval Cohen, the CEO, will engage in a fireside chat and investor meetings on May 14-15, 2024, in New York. The event will include a webcast on May 14 at 9:30 a.m. ET.
Corbus Pharmaceuticals reported its first-quarter 2024 financial results, highlighting the dosing of the first patient in the U.S. Phase 1 clinical trial of CRB-701, targeting Nectin-4. The company raised $116 million in capital, extending its cash runway through Q1 2027, and appointed Dr. Dominic Smethurst as Chief Medical Officer. CRB-701 Phase 1 data will be presented at ASCO Annual Meeting on June 1, 2024.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) will participate in the BTIG Obesity Health Forum with CEO Yuval Cohen joining a panel discussion on CB1 Axis Therapies for Obesity on May 8, 2024. The event will be held virtually, offering insights into the company's innovative approaches to addressing obesity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.